Notice of Intent to Publish a Funding Opportunity Announcement: Grand Opportunity in Medications Development for Substance-Related Disorders (U01)

Notice Number: NOT-DA-11-003

Update: The following update relating to this Notice has been issued:

  • May 24, 2011 - See PAR-11-109 Grand Opportunity in Medications Development for Substance-Related Disorders (U01).

Key Dates
Release Date: December 6, 2010

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to promote a new research initiative by publishing a Funding Opportunity Announcement (FOA) that will solicit applications for studies that will accelerate the development of medications for the treatment of Substance-Related Disorders (SRDs). The purpose of the FOA is to fund pivotal medication studies that will have high impact and quickly yield the necessary results to advance medications to FDA approval. These studies will be supported by the U01 cooperative agreement funding mechanism, which will include a significant scientific and programmatic involvement of NIDA staff. Applications for a diverse array of preclinical and/or clinical research projects are expected. Applications for up to 3 years and for a budget of up to $5 million per year will be acceptable. This notice is being provided to allow potential applicants sufficient time to develop high-quality and responsive projects.

The FOA is expected to be published early in 2011 with an expected receipt date in the spring of 2011.

Details of the planned Funding Opportunity Announcement (FOA) are provided below.

Research Initiative Details

This Notice encourages investigators interested in the development of medications to treat SRDs to consider applying for this new FOA.

The FOA will encourage pre-clinical and/or clinical research projects intending to evaluate the safety and/or efficacy of medications for the treatment of SRDs. The goal accelerate the development of medications for the treatment of SRDs by funding pivotal studies that will have high impact and will quickly yield the necessary results to advance medications to FDA approval.

APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Ivan D. Montoya, M.D., M.P.H.
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd. Room Number 4143
Bethesda, MD 20892
Telephone: (301) 443-8639
Fax: 301-443-2599
Email: imontoya@mail.nih.gov